

Gambro polyflux h

DESIGNED FOR EFFECTIVE HIGH FLUX, HEMODIAFILTRATION AND HEMOFILTRATION TREATMENTS (HFHD, HDF, HF)^{1,2}

The Gambro POLYFLUX H dialyzer has an established heritage of use in convective treatments, facilitating the achievement of target convective volume and providing effective clearance of middle molecules such as β_2 microglobulin (β_2m).³⁻⁶ The exclusive asymmetric three-layer POLYAMIX membrane has been designed to facilitate transport of fluid and solutes across the membrane, help to prevent the loss of essential proteins such as albumin, and promote biocompatibility.^{7,8}

CONSISTENT MOLECULAR CLEARANCE AND RETENTION

- Effective removal of middle molecules such as β_2m and minimal loss of essential proteins throughout dialysis^{7,9-11}
- POLYAMIX membrane is designed for endotoxin retention^{2,12-13}

VERSATILE MEMBRANE DESIGN

- Proprietary membrane approved for use in hemodiafiltration, hemofiltration and high flux hemodialysis therapies¹
- 3-layer membrane structure designed to provide high transport rates²
- Membrane microstructure promotes biocompatibility^{2,14}
- Designed to help minimize the risk of clotting²

DESIGNED FOR THE PATIENT

- Steam sterilized, which eliminates exposing patients to potential EtO residuals and helps to reduce the risk of possible cytotoxic effects due to gamma irradiation^{2,15,16}
- Removable patient label available to streamline documentation and help avoid charting errors



TYPICAL PATIENT PROFILE:
HEMODIAFILTRATION (HDF) PATIENTS

Gambro POLYFLUX H Dialyzer

PERFORMANCES IN VITRO

Measured according to ISO 8637

CLEARANCE IN VITRO

(ml/min) ± 10%

Hemodialysis

UF=0 ml/min, Q_D=500 ml/min, Q_B (ml/min)

	POLYFLUX 140H				POLYFLUX 170H				POLYFLUX 210H			
	200	300	400	500	200	300	400	500	200	300	400	500
Urea	193	262	309	–	196	270	321	–	–	281	339	378
Creatinine	181	232	266	–	186	243	281	–	–	259	303	334
Phosphate	174	220	250	–	180	232	266	–	–	249	289	317
Vitamin B ₁₂	128	149	163	–	137	162	178	–	–	183	203	218
Inulin	91	102	109	–	100	113	121	–	–	131	143	151

Hemodiafiltration

UF=60 ml/min, Q_D=500 ml/min, Q_B (ml/min)

Urea	198	277	332	–	199	283	343	–	–	290	359	406
Creatinine	191	252	292	–	194	262	306	–	–	274	327	363
Phosphate	187	242	277	–	191	252	292	–	–	266	314	347
Vitamin B ₁₂	152	177	193	–	159	189	208	–	–	208	232	249
Inulin	120	133	141	–	128	143	153	–	–	161	174	183

SPECIFICATIONS

KoA for urea*	998	1153	1452
Ultra filtration** (ml/min) ± 10%, measured at Q _B =300 ml/min and TMP=300 mmHg	113	127	144
UF-coefficient** (ml/h·mmHg)	60	70	85
Priming volume (ml)	94	115	125
Fluid volume for priming (ml)		≥500	
Residual blood volume (ml)	<1	<1	~1
Maximum TMP (mmHg)		600	
Recommended Q _B (ml/min)	200-400	250-500	300-500
Sieving coefficient***			
Vitamin B ₁₂		1.0	
Inulin		1.0	
β ₂ -microglobulin		0.7	
Albumin		<0.01	
Membrane			
Surface area (m ²)	1.4	1.7	2.1
Fiber dimensions			
Wall thickness (μm)		50	
Inner diameter (μm)		215	

COMPONENTS	MATERIALS	STERILIZATION AGENT	STERILE BARRIER	QUANTITY PER CASE
Membrane	POLYAMIX****	Steam	Medical grade paper	24
Potting material	Polyurethane (PUR)			
Housing, caps	Polycarbonate (PC)			
Protective caps	Polypropylene (PP)			
O-ring	Silicon rubber (SIR)			

* Calculated at Q_B=300 ml/min, Q_D=500 ml/min and UF=0.

** Measured with bovine blood, hematocrit of (32 ± 3) %, protein content of (60 ± 5) g/l at 37 °C.

*** Typical values measured with Polyflux 170H dialyzer, with bovine plasma, a protein content of (60 ± 5) g/l at 37 °C. Sieving coefficient determined at a filtration rate of 0.70x10⁻⁴ cm/s and a wall shear rate of 461 s⁻¹.

**** Polyarylethersulfone, Polyvinylpyrrolidone, Polyamide blend.



Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015
USA
1-800-422-9837

1. Baxter. POLYFLUX H. Instruction for use. 2009. 2. Ronco C, et al. *Nephrol Dial Transplant* 2003; 18(Suppl 7):vii10–20. 3. Panichi V, et al. *Int J Artif Org* 2012; 35 (6):435–443. 4. Teatini U, et al. *Blood Purif* 2011; 31:259–267. 5. Meert N, et al. *Nephrol Dial Transplant* 2009; 24:562–570. 6. Penne E, et al. *Nephrol Dial Transplant* 2009; 24(12):3579–3581. 7. Joyeux V, et al. *Int J Artif Organs* 2008; 31(11):928–936. 8. Girndt M, et al. *Eur J Clin Invest* 2015. [ePub ahead of print]. 9. Krieter DH, et al. *Artif Organs* 2008; 32:547–554. 10. Ouseph R, et al. *Nephrol Dial Transplant* 2008; 23:1704–1712. 11. Lonnemann G, et al. *Clin Nephrol* 2009; 72:170–176. 12. Hoenich NA, et al. *ASAIO J* 2000; 46:70–75. 13. Ertl T, et al. *Blood Purif* 2003; 21:358. 14. Li Z, et al. *Ren Fail* 2015; [Epub ahead of print]:1–5. 15. Krause B, et al. *Chemie Ingenieur Technik* 2003; 75:1725–1732. 16. D'Ambrosio FP, et al. *Nephrol Dial* 1997; 12:1461–1463.

Baxter, Gambro, Polyamix and Polyflux are trademarks of Baxter International Inc. or its subsidiaries.